39 Table 2: Trial Phase and Number of Drugs Studied in the 224 MBC Clinical Trials Table continued next page Trial Category No. of Trials No. of Drugs under Study* No. of Phase I No. of Phase I/II No. of Phase II No. of Phase III Targeted Trials Assigned to Hallmark of Cancer Category (n=162) 1. Sustaining Proliferative Signaling (n=95) Total 95 69 41 7 38 9 PI3/Akt/mTOR 37 26 17 4 13 3 JAK 2 1 0 1 1 0 Notch 3 2 3 0 0 0 RAF/MEK/ERK/ALK 4 4 2 0 2 0 IGF 1 1 0 1 0 0 ERB receptors 29 20 11 0 13 5 Hormone-mediated 13 10 6 0 6 1 PTEN Mutation 1 1 1 0 0 0 Other 5 4 1 1 3 0 2. Evading Growth Suppressors (n=9) Cyclin-Dependent Kinase Inhibitors 9 3 3 2 1 3 3. Inducing Angiogenesis (n=4) VEGF Signaling Inhibitors 4 4 3 0 0 1 4. Resisting Cell Death (n=1) IAP (Inhibit apoptosis proteins) 1 1 1 0 0 0 5. Enabling Replicative Immortality (n=0) Telomerase Inhibitors 0 0 0 0 0 0 6. Genome Instability and Mutation (n=25) Total 25 10 11 6 4 4 PARP Inhibitors 16 5 8 3 3 2 HDAC Inhibitors 8 4 3 3 0 2 Other 1 1 0 0 1 0